Post-cancer fatigue “overestimated"

 

Sydney, Australia (April 26, 2012) – Despite widespread belief to the contrary, as few as 6 percent of women experience cancer-related persistent fatigue a year after undergoing treatment for breast cancer, a new study has found.

Prolonged and disabling fatigue is a common side-effect of many cancer treatments, with large numbers of women reporting that cancer-related fatigue persists for many months after treatment ends. Some studies put the figure as high as 50 percent.

 

But a study of breast cancer survivors from a group of collaborating hospitals in Sydney together with staff of the UNSW’s newly established Cancer Survivors’ Centre has found that figure is overstated, with the previously reported high rates of fatigue most likely attributable to factors unrelated to the cancer or its treatment.

 

And while the study, published this month in Journal of Clinical Oncology, looked at breast cancer, the researchers believe the same results would apply to survivors of other cancers.

 

“The good news is that the vast majority of women who have undergone cancer treatment either never experience ongoing debilitating fatigue in the weeks and months after treatment ends or if they do, it passes relatively quickly,” said study author, Professor David Goldstein, from UNSW’s Prince of Wales Clinical School.

 

“This is not to say that cancer-related fatigue is not a problem. It is still one of the main symptoms of cancer and a major side effect of treatment, but people can be reassured that for the vast majority receiving adjuvant treatment, it is not an ongoing or long term debilitating experience,” Professor Goldstein said.

 

The 5-year prospective study followed 218 women with early-stage breast cancer. The women were observed and questioned at three-monthly intervals for a year after treatment and again at five years. A rigorous definition of fatigue was used to rule out any “background” fatigue.

 

The study found the case rate for cancer-related fatigue fell from 31 percent at the end of treatment to 11 percent at six months and 6 percent at 12 months.

 

The findings suggest that previous studies have overestimated the prevalence of cancer-related fatigue and included transient fatigue states associated with unrelated infections, surgery and minor psychiatric disorders and chronic fatigue states attributable to other conditions.

 

The researchers say for the significant minority of people (6%) who do experience ongoing fatigue, attention can now be focussed on early identification and directing resources where they are most needed.

 

The success of cancer treatments and the increasing number of cancer survivors makes finding find better ways to manage survivorship essential. Researchers believe exercise may be one key element.

 

To that end, the UNSW Cancer Survivors’ Centre, in conjunction with one of its partners the UNSW Lifestyle Clinic, has begun trials of a twelve-week intensive program of exercise and cognitive behaviour therapy to help people with established cancer-related fatigue.

 

“Exercise is increasingly being identified as a medicine, potentially even with a dose response, and it may have a very important role as a therapy not only in cancer recovery but also in the treatment process itself,” Professor Goldstein said.

 

UNSW’s Cancer Survivor Centre is the first comprehensive centre in Australia and is also one of very few worldwide to focus on survivors of both childhood and adult cancers.

 


 

Universtity of New South Wales (UNSW), Australia, 26.04.2012 (tB).

MEDICAL NEWS

COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…